Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway

References

• Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–1064.
   PubMed Web of Science ®Google Scholar
• Ghose A, Bolina A, Mahajan I, et al. Hereditary ovarian cancer: towards a cost-effective prevention strategy. Int J Environ Res Public Health. 2022;19(19). doi:10.3390/ijerph191912057
   Web of Science ®Google Scholar
• Schoutrop E, Moyano-Galceran L, Lheureux S, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semi Cancer Biol. 2022;86(Pt 3):207–223. doi:10.1016/j.semcancer.2022.03.027
   PubMedGoogle Scholar
• Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20(12):820–842. doi:10.1038/s41571-023-00819-1
   PubMed Web of Science ®Google Scholar
• Handley KF, Sims TT, Bateman NW, et al. Classification of high-grade serous ovarian cancer using tumor morphologic characteristics. JAMA network open. 2022;5(10):e2236626. doi:10.1001/jamanetworkopen.2022.36626
   PubMed Web of Science ®Google Scholar
• Pavlik EJ, Smith C, Dennis TS, et al. Disease-specific survival of type I and type II epithelial ovarian cancers-stage challenges categorical assignments of indolence & aggressiveness. Diagnostics. 2020;10(2). doi:10.3390/diagnostics10020056
   Web of Science ®Google Scholar
• Barnes BM, Nelson L, Tighe A, et al. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med. 2021;13(1):140. doi:10.1186/s13073-021-00952-5
   PubMed Web of Science ®Google Scholar
• Shu C, Zheng X, Wuhafu A, et al. Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. Acta Pharmacol. Sin. 2022;43(9):2419–2428. doi:10.1038/s41401-021-00847-6
   PubMed Web of Science ®Google Scholar
• Tendulkar S, Dodamani S. Chemoresistance in ovarian cancer: prospects for new drugs. Anti Cancer Agent Med Chem. 2021;21(6):668–678. doi:10.2174/1871520620666200908104835
   PubMed Web of Science ®Google Scholar
• Ghose A, McCann L, Makker S, et al. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Therapeut Adv Med Oncol. 2024;16:17588359241233225. doi:10.1177/17588359241233225
   Web of Science ®Google Scholar
• Ahmed Khalil A, Rauf A, Alhumaydhi FA, et al. Recent developments and anticancer therapeutics of paclitaxel: an update. Curr. Pharm. Des. 2022;28(41):3363–3373. doi:10.2174/1381612829666221102155212
   PubMed Web of Science ®Google Scholar
• Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742. doi:10.1016/j.drup.2020.100742
   PubMed Web of Science ®Google Scholar
• Zhao S, Tang Y, Wang R, Najafi M. Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis. 2022;27(9–10):647–667. doi:10.1007/s10495-022-01750-z
   PubMed Web of Science ®Google Scholar
• Faria RS, De lima LI, Bonadio RS, et al. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer. Biomed Pharmacothe. 2021;142:112000. doi:10.1016/j.biopha.2021.112000
   PubMed Web of Science ®Google Scholar
• Jaunky DB, Larocque K, Husser MC, Liu JT, Forgione P, Piekny A. Characterization of a recently synthesized microtubule-targeting compound that disrupts mitotic spindle Poles in human cells. Sci Rep. 2021;11(1):23665. doi:10.1038/s41598-021-03076-3
   PubMed Web of Science ®Google Scholar
• Sazonova EV, Petrichuk SV, Kopeina GS, Zhivotovsky B. A link between mitotic defects and mitotic catastrophe: detection and cell fate. Biology Direct. 2021;16(1):25. doi:10.1186/s13062-021-00313-7
   PubMed Web of Science ®Google Scholar
• Drosos Y, Konstantakou EG, Bassogianni AS, et al. Microtubule dynamics deregulation induces apoptosis in human urothelial bladder cancer cells via a p53-independent pathway. Cancers. 2023;15(14):2.
   Web of Science ®Google Scholar
• Ren X, Zhao B, Chang H, Xiao M, Wu Y, Liu Y. Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells. Mol Med Rep. 2018;17(6):8289–8299. doi:10.3892/mmr.2018.8868
   PubMed Web of Science ®Google Scholar
• Pan Z, Avila A, Gollahon L. Paclitaxel induces apoptosis in breast cancer cells through different calcium--regulating mechanisms depending on external calcium conditions. Int J Mol Sci. 2014;15(2):2672–2694. doi:10.3390/ijms15022672
   PubMed Web of Science ®Google Scholar
• Miller AV, Hicks MA, Nakajima W, Richardson AC, Windle JJ, Harada H. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor. PLoS One. 2013;8(4):e60685. doi:10.1371/journal.pone.0060685
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu X, Zhang F, et al. Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727. Oncol Rep. 2017;37(4):2237–2244. doi:10.3892/or.2017.5503
   PubMed Web of Science ®Google Scholar
• He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. doi:10.1038/s41392-021-00828-5
   PubMed Web of Science ®Google Scholar
• Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semi Cancer Biol. 2022;85:253–275. doi:10.1016/j.semcancer.2022.04.002
   PubMed Web of Science ®Google Scholar
• Rosenkranz AA, Slastnikova TA. Epidermal growth factor receptor: key to selective intracellular delivery. Biochem Biokhimiia. 2020;85(9):967–1092. doi:10.1134/s0006297920090011
   PubMed Web of Science ®Google Scholar
• Bai X, Sun P, Wang X, et al. Structure and dynamics of the EGFR/HER2 heterodimer. Cell Discovery. 2023;9(1):18. doi:10.1038/s41421-023-00523-5
   PubMed Web of Science ®Google Scholar
• Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers. 2021;13(11):3.
   Web of Science ®Google Scholar
• Lipsick J. A history of cancer research: tyrosine kinases. Cold Spring Harbor Perspect Biol. 2019;11(2):3.
   Web of Science ®Google Scholar
• Xu H, Zong H, Ma C, et al. Epidermal growth factor receptor in glioblastoma. Oncol Lett. 2017;14(1):512–516. doi:10.3892/ol.2017.6221
   PubMed Web of Science ®Google Scholar
• Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48–51.
   PubMedGoogle Scholar
• Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16(1):102–108. doi:10.1093/annonc/mdi006
   PubMed Web of Science ®Google Scholar
• Rehmani HS, Issaeva N. EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations. Ann Transl Med. 2020;8(13):813. doi:10.21037/atm.2020.04.07
   PubMed Web of Science ®Google Scholar
• Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers. 2011;3(2):1513–1526. doi:10.3390/cancers3021513
   PubMedGoogle Scholar
• Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331–345. doi:10.1007/s10549-012-2289-9
   PubMed Web of Science ®Google Scholar
• Thakur A, Faujdar C, Sharma R, et al. Glioblastoma: current status, emerging targets, and recent advances. J Med Chem. 2022;65(13):8596–8685. doi:10.1021/acs.jmedchem.1c01946
   PubMed Web of Science ®Google Scholar
• Smolle E, Leithner K, Olschewski H. Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: clinical significance and limitations. Thorac Cancer. 2020;11(2):205–215. doi:10.1111/1759-7714.13246
   PubMed Web of Science ®Google Scholar
• Amisha F, Malik P, Saluja P, et al. A comprehensive review on the role of human epidermal growth factor receptor 2 (HER2) as a biomarker in extra-mammary and extra-gastric cancers. Onco. 2023;3(2):96–124.
   Google Scholar
• Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer. 2011;104(8):1241–1245.
   PubMed Web of Science ®Google Scholar
• Mehner C, Oberg AL, Goergen KM, et al. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes Cancer. 2017;8(5–6):589–599. doi:10.18632/genesandcancer.142
   PubMedGoogle Scholar
• Forlani L, De Cecco L, Simeon V, et al. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the Phase IV ovarian cancer MITO-16A/Mango-OV2A trial. J Experiment Clin Cancer Res. 2023;42(1):83. doi:10.1186/s13046-023-02651-y
   PubMed Web of Science ®Google Scholar
• Schultz DF, Billadeau DD, Jois SD. EGFR trafficking: effect of dimerization, dynamics, and mutation. Front Oncol. 2023;13:1258371. doi:10.3389/fonc.2023.1258371
   PubMed Web of Science ®Google Scholar
• Bakker J, Spits M, Neefjes J, Berlin I. The EGFR odyssey - from activation to destruction in space and time. J Cell Sci. 2017;130(24):4087–4096. doi:10.1242/jcs.209197
   PubMed Web of Science ®Google Scholar
• Melikova MS, Kondratov KA, Kornilova ES. Two different stages of epidermal growth factor (EGF) receptor endocytosis are sensitive to free ubiquitin depletion produced by proteasome inhibitor MG132. Cell Biol Int. 2006;30(1):31–43. doi:10.1016/j.cellbi.2005.09.003
   PubMed Web of Science ®Google Scholar
• Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol. 2002;156(5):843–854. doi:10.1083/jcb.200106056
   PubMed Web of Science ®Google Scholar
• Oksvold MP, Skarpen E, Wierod L, Paulsen RE, Huitfeldt HS. Re-localization of activated EGF receptor and its signal transducers to multivesicular compartments downstream of early endosomes in response to EGF. Eur J Cell Biol. 2001;80(4):285–294. doi:10.1078/0171-9335-00160
   PubMed Web of Science ®Google Scholar
• Zhou Y, Sakurai H. New trend in ligand-induced EGFR trafficking: a dual-mode clathrin-mediated endocytosis model. J Proteom. 2022;255:104503. doi:10.1016/j.jprot.2022.104503
   PubMed Web of Science ®Google Scholar
• Yao N, Wang C-R, Liu M-Q, et al. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Sig Transd Targ Ther. 2020;5(1):1–13.
   PubMed Web of Science ®Google Scholar
• Xiao D, Hu X, Peng M, et al. Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy. Cell Death Dis. 2022;13(5):499. doi:10.1038/s41419-022-04937-z
   PubMed Web of Science ®Google Scholar
• Lin ZY, Yun QZ, Wu L, Zhang TW, Yao TZ. Pharmacological basis and new insights of deguelin concerning its anticancer effects. Pharmacol Res. 2021;174:105935. doi:10.1016/j.phrs.2021.105935
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang M, Mellich TA, Pearson BJ, Chen J, Zhang Z. Variation in rotenone and deguelin contents among strains across four tephrosia species and their activities against aphids and whiteflies. Toxins. 2022;14(5):3.
   Web of Science ®Google Scholar
• Ibarra-Gutiérrez MT, Serrano-García N, Orozco-Ibarra M. Rotenone-induced model of parkinson’s disease: beyond mitochondrial complex I inhibition. Molec Neurobiol. 2023;60(4):1929–1948. doi:10.1007/s12035-022-03193-8
   PubMedGoogle Scholar
• Thirugnanam T, Santhakumar K. Chemically induced models of Parkinson’s disease. Comp Biochem Physiol Toxicol Pharmacol. 2022;252:109213. doi:10.1016/j.cbpc.2021.109213
   PubMed Web of Science ®Google Scholar
• Boyd J, Han A. Deguelin and its role in chronic diseases. Adv Exp Med Biol. 2016;929:363–375. doi:10.1007/978-3-319-41342-6_16
   PubMed Web of Science ®Google Scholar
• Baba Y, Kato Y. Deguelin, a novel anti-tumorigenic agent in human esophageal squamous cell carcinoma. EBioMedicine. 2017;26:10. doi:10.1016/j.ebiom.2017.11.010
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma W, Zheng W. Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Mol Clin Oncol. 2013;1(2):215–219. doi:10.3892/mco.2012.36
   PubMedGoogle Scholar
• Hu J, Ye H, Fu A, et al. Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model. Int, J, Cancer. 2010;127(10):2455–2466. doi:10.1002/ijc.25253
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Cartner LK, Wilson JA, et al. Deguelins, natural product modulators of NF1-defective astrocytoma cell growth identified by high-throughput screening of partially purified natural product extracts. J Nat Prod. 2015;78(11):2776–2781. doi:10.1021/acs.jnatprod.5b00753
   PubMed Web of Science ®Google Scholar
• Li W, Gao F, Ma X, Wang R, Dong X, Wang W. Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis. Oncotarget. 2017;8(20):32586.
   PubMedGoogle Scholar
• Li M, Yu X, Li W, et al. Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway. Oncotarget. 2018;9(1):152.
   PubMedGoogle Scholar
• Chen L, Jiang K, Chen H, et al. Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway. Cancer Manage Res. 2019;11:95.
   PubMed Web of Science ®Google Scholar
• Yu X, Liang Q, Liu W, Zhou L, Li W, Liu H. Deguelin, an Aurora B kinase inhibitor, exhibits potent anti-tumor effect in human esophageal squamous cell carcinoma. EBioMedicine. 2017;26:100–111.
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Chagani S, Nelson D, et al. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib‐resistant BRAFV600E mutation bearing metastatic melanoma cells. Molec Carcinogene. 2019;58(9):1680–1690.
   PubMed Web of Science ®Google Scholar
• Kim HS, Hoang V-H, Hong M, et al. Investigation of B, C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents. Bioorg. Med. Chem. 2019;27(7):1370–1381.
   PubMed Web of Science ®Google Scholar
• Varughese RS, Lam WST, Marican AA, et al. Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential. Cancer. 2019;125(11):1789–1798.
   PubMed Web of Science ®Google Scholar
• Li W, Yu X, Xia Z, et al. Repression of Noxa by Bmi1 contributes to deguelin‐induced apoptosis in non‐small cell lung cancer cells. J Cell & Mol Med. 2018;22(12):6213–6227.
   PubMed Web of Science ®Google Scholar
• Li W, Yu X, Ma X, et al. Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway. Cell. Signalling. 2018;50:131–141.
   PubMed Web of Science ®Google Scholar
• Martincuks A, Li PC, Zhao Q, et al. CD44 in ovarian cancer progression and therapy resistance-A critical role for STAT3. Front Oncol. 2020;10:589601. doi:10.3389/fonc.2020.589601
   PubMed Web of Science ®Google Scholar
• Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C. ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. Int J Mol Sci. 2019;20:2.
   Web of Science ®Google Scholar
• Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021;2(3):315–340. doi:10.1002/mco2.55
   PubMedGoogle Scholar
• Gao F, Yu X, Li M, et al. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3beta/FBW7-mediated Mcl-1 destabilization. Cell Death Dis. 2020;11(2):143. doi:10.1038/s41419-020-2344-0
   PubMed Web of Science ®Google Scholar
• Murillo G, Peng X, Torres KE, Mehta RG. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res. 2009;2(11):942–950. doi:10.1158/1940-6207.CAPR-08-0232
   PubMed Web of Science ®Google Scholar
• Yang YL, Ji C, Bi ZG, et al. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PLoS One. 2013;8(1):e54736. doi:10.1371/journal.pone.0054736
   PubMed Web of Science ®Google Scholar
• Pote MS, Gacche RN. ATP-binding cassette efflux transporters and MDR in cancer. Drug Discovery Today. 2023;28(5):103537. doi:10.1016/j.drudis.2023.103537
   PubMed Web of Science ®Google Scholar
• Pilotto Heming C, Muriithi W, Wanjiku Macharia L, Niemeyer Filho P, Moura-Neto V, Aran V. P-glycoprotein and cancer: what do we currently know? Heliyon. 2022;8(10):e11171. doi:10.1016/j.heliyon.2022.e11171
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22(47):7468–7485. doi:10.1038/sj.onc.1206948
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Gholami MH, Hashemi F, et al. Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects. Drug Discovery Today. 2022;27(2):436–455. doi:10.1016/j.drudis.2021.09.020
   PubMed Web of Science ®Google Scholar
• Orlicky J, Sulova Z, Dovinova I, Fiala R, Zahradnikova A, Breier A. Functional fluo-3/AM assay on P-glycoprotein transport activity in L1210/VCR cells by confocal microscopy. Gen Physiol Biophys. 2004;23(3):357–366.
   PubMed Web of Science ®Google Scholar
• Liang X, Huang Y. Intracellular free calcium concentration and cisplatin resistance in human lung adenocarcinoma A549 cells. Biosci Rep. 2000;20(3):129–138. doi:10.1023/a:1005530501137
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang Y, Tang X, Wang Y, Zhang Z, Yang H. Paclitaxel induces the apoptosis of prostate cancer cells via ROS-mediated HIF-1alpha expression. Molecules. 2022;27(21):3.
   Web of Science ®Google Scholar
• Glaviano A, Foo ASC, Lam HY, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. doi:10.1186/s12943-023-01827-6
   PubMed Web of Science ®Google Scholar
• Koundouros N, Poulogiannis G. Phosphoinositide 3-Kinase/Akt Signaling and redox metabolism in cancer. Front Oncol. 2018;8:160. doi:10.3389/fonc.2018.00160
   PubMed Web of Science ®Google Scholar
• Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797. doi:10.1038/s41419-020-02998-6
   PubMed Web of Science ®Google Scholar
• Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Invest Drugs. 2022;31(6):607–631. doi:10.1080/13543784.2022.2067527
   PubMed Web of Science ®Google Scholar
• Ding L, Kim HJ, Wang Q, et al. PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972–2980.e5. doi:10.1016/j.celrep.2018.11.054
   PubMed Web of Science ®Google Scholar
• Aliyuda F, Moschetta M, Ghose A, et al. Advances in ovarian cancer treatment beyond PARP inhibitors. Curr Cancer Drug Targets. 2023;23(6):433–446. doi:10.2174/1568009623666230209121732
   PubMed Web of Science ®Google Scholar
• Mahadevan J, Jha A, Rudolph J, et al. Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging. iScience. 2023;26(1):105779. doi:10.1016/j.isci.2022.105779
   PubMed Web of Science ®Google Scholar
• Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed Pharmacother. 2020;123:109661. doi:10.1016/j.biopha.2019.109661
   PubMed Web of Science ®Google Scholar
• Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y. A new wave of innovations within the DNA damage response. Signal Transduct Target Ther. 2023;8(1):338. doi:10.1038/s41392-023-01548-8
   PubMed Web of Science ®Google Scholar
• Wang M, Chen S, Ao D. Targeting DNA repair pathway in cancer: mechanisms and clinical application. MedComm. 2021;2(4):654–691. doi:10.1002/mco2.103
   PubMedGoogle Scholar
• Patel A, Kalachand R, Busschots S, et al. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2022;7(7):Cd008766. doi:10.1002/14651858.CD008766.pub3
   PubMedGoogle Scholar
• Garrido MP, Fredes AN, Lobos-González L, Valenzuela-Valderrama M, Vera DB, Romero C. Current treatments and new possible complementary therapies for epithelial ovarian cancer. Biomedicines. 2021;10:1.
   PubMed Web of Science ®Google Scholar
• Su M, Zhang Z, Zhou L, Han C, Huang C, Nice EC. Proteomics, personalized medicine and cancer. Cancers. 2021;13(11). doi:10.3390/cancers13112512
   Web of Science ®Google Scholar
• Ghose A, Gullapalli SVN, Chohan N, et al. Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes. 2022;10(2):2.
   PubMed Web of Science ®Google Scholar
• Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem. 1992;267(8):5317–5323.
   PubMed Web of Science ®Google Scholar
• Singer TP, Ramsay RR. The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. Biochim Biophys Acta. 1994;1187(2):198–202. doi:10.1016/0005-2728(94)90110-4
   PubMed Web of Science ®Google Scholar
• Kang W, Zheng X, Wang P, Guo S. Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro. IntJ Mol Med. 2018;41(6):3157–3166. doi:10.3892/ijmm.2018.3532
   PubMed Web of Science ®Google Scholar
• Tuli HS, Mittal S, Loka M, et al. Deguelin targets multiple oncogenic signaling pathways to combat human malignancies. Pharmacol Res. 2021;166:105487. doi:10.1016/j.phrs.2021.105487
   PubMed Web of Science ®Google Scholar
• Lokhande KB, Nagar S, Swamy KV. Molecular interaction studies of Deguelin and its derivatives with Cyclin D1 and Cyclin E in cancer cell signaling pathway: the computational approach. Sci Rep. 2019;9(1):1778. doi:10.1038/s41598-018-38332-6
   PubMedGoogle Scholar
• Xu H, Li X, Ding W, et al. Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway. Cancer Cell Int. 2015;15:25. doi:10.1186/s12935-015-0166-4
   PubMed Web of Science ®Google Scholar
• Mehta R, Katta H, Alimirah F, et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One. 2013;8(6):e65113. doi:10.1371/journal.pone.0065113
   PubMed Web of Science ®Google Scholar
• Wang Y, Lan Y, Wu L, Zhang S, Su Q, Yang Q. Deguelin and paclitaxel loaded PEG-PCL nano-micelles for suppressing the proliferation and inducing apoptosis of breast cancer cells. Front Biosci. 2024;29(2):90. doi:10.31083/j.fbl2902090
   Web of Science ®Google Scholar
• Wordeman L, Vicente JJ. Microtubule targeting agents in disease: classic drugs, novel roles. Cancers. 2021;13(22):2.
   Web of Science ®Google Scholar
• Li H, Duan ZW, Xie P, et al. Effects of paclitaxel on EGFR endocytic trafficking revealed using quantum dot tracking in single cells. PLoS One. 2012;7(9):e45465. doi:10.1371/journal.pone.0045465
   PubMed Web of Science ®Google Scholar
• Martin-Fernandez ML, Clarke DT, Tobin MJ, Jones GR. Real-time studies of the interactions between epidermal growth factor and its receptor during endocytic trafficking. Cell Mol Biol. 2000;46(6):1103–1112.
   PubMed Web of Science ®Google Scholar
• Hampton KK, Craven RJ. Pathways driving the endocytosis of mutant and wild-type EGFR in cancer. Oncoscience. 2014;1(8):504–512. doi:10.18632/oncoscience.67
   PubMedGoogle Scholar
• Tanaka T, Zhou Y, Ozawa T, et al. Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation. J Biol Chem. 2018;293(7):2288–2301. doi:10.1074/jbc.M117.811299
   PubMed Web of Science ®Google Scholar
• Rush JS, Quinalty LM, Engelman L, Sherry DM, Ceresa BP. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chem. 2012;287(1):712–722. doi:10.1074/jbc.M111.294470
   PubMed Web of Science ®Google Scholar
• Papagiannouli F. Endocytosis at the crossroad of polarity and signaling regulation: learning from drosophila melanogaster and beyond. Int J Mole Sci. 2022;23(9):4.
   Web of Science ®Google Scholar
• Yao N, Wang CR, Liu MQ, et al. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Sig Transd Targ Ther. 2020;5(1):214. doi:10.1038/s41392-020-00251-2
   PubMed Web of Science ®Google Scholar
• Cui H, Arnst K, Miller DD, Li W. Recent advances in elucidating paclitaxel resistance mechanisms in non-small cell lung cancer and strategies to overcome drug resistance. Curr Med Chem. 2020;27(39):6573–6595. doi:10.2174/0929867326666191016113631
   PubMed Web of Science ®Google Scholar
• Das T, Anand U, Pandey SK, et al. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updates. 2021;55:100754. doi:10.1016/j.drup.2021.100754
   PubMed Web of Science ®Google Scholar
• Nunes M, Silva PMA, Coelho R, et al. Generation of two paclitaxel-resistant high-grade serous carcinoma cell lines with increased expression of p-glycoprotein. Front Oncol. 2021;11:752127. doi:10.3389/fonc.2021.752127
   PubMed Web of Science ®Google Scholar
• Prota AE, Lucena-Agell D, Ma Y, et al. Structural insight into the stabilization of microtubules by taxanes. eLife. 2023:12. doi:10.7554/eLife.84791
   Web of Science ®Google Scholar
• Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther. 2006;5(2):270–278. doi:10.1158/1535-7163.MCT-05-0190
   PubMed Web of Science ®Google Scholar
• Xiao H, Zheng Y, Ma L, Tian L, Sun Q. Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol. 2021;12:648407. doi:10.3389/fphar.2021.648407
   PubMed Web of Science ®Google Scholar
• Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review). Int j Oncol. 2023;63:5.
   Web of Science ®Google Scholar
• Alatise KL, Gardner S, Alexander-Bryant A. Mechanisms of drug resistance in ovarian cancer and associated gene targets. Cancers. 2022;14(24). doi:10.3390/cancers14246246
   PubMed Web of Science ®Google Scholar
• Los M, Maddika S, Erb B, Schulze-Osthoff K. Switching Akt: from survival signaling to deadly response. Bioessays. 2009;31(5):492–495. doi:10.1002/bies.200900005
   PubMed Web of Science ®Google Scholar
• Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997;11(6):701–713. doi:10.1101/gad.11.6.701
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857–868. doi:10.1016/s0092-8674(00)80595-4
   PubMed Web of Science ®Google Scholar
• Adil MS, Khulood D, Somanath PR. Targeting Akt-associated microRNAs for cancer therapeutics. Biochem. Pharmacol. 2021;189:114384. doi:10.1016/j.bcp.2020.114384
   PubMed Web of Science ®Google Scholar
• Mundi PS, Sachdev J, McCourt C, Kalinsky K. AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol. 2016;82(4):943–956. doi:10.1111/bcp.13021
   PubMed Web of Science ®Google Scholar
• Nasimian A, Farzaneh P, Tamanoi F, Bathaie SZ. Cytosolic and mitochondrial ROS production resulted in apoptosis induction in breast cancer cells treated with Crocin: the role of FOXO3a, PTEN and AKT signaling. Biochem Pharmacol. 2020;177:113999. doi:10.1016/j.bcp.2020.113999
   PubMed Web of Science ®Google Scholar
• Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell. 2020;38(2):167–197. doi:10.1016/j.ccell.2020.06.001
   PubMed Web of Science ®Google Scholar
• Perillo B, Di Donato M, Pezone A, et al. ROS in cancer therapy: the bright side of the moon. Experiment Mole Med. 2020;52(2):192–203. doi:10.1038/s12276-020-0384-2
   PubMed Web of Science ®Google Scholar
• Nakamura H, Takada K. Reactive oxygen species in cancer: current findings and future directions. Cancer Sci. 2021;112(10):3945–3952. doi:10.1111/cas.15068
   PubMed Web of Science ®Google Scholar
• Ghoneum A, Said N. PI3K-AKT-mTOR and NFκB pathways in ovarian cancer: implications for targeted therapeutics. Cancers. 2019;11:7.
   Web of Science ®Google Scholar
• Huang TT, Lampert EJ, Coots C, Lee JM. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev. 2020;86:102021. doi:10.1016/j.ctrv.2020.102021
   PubMed Web of Science ®Google Scholar
• Rinne N, Christie EL, Ardasheva A, et al. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist. 2021;4(3):573–595. doi:10.20517/cdr.2021.05
   PubMedGoogle Scholar
• Steven A, Friedrich M, Jank P, et al. What turns CREB on? And off? And why does it matter? Cell Mol Life Sci. 2020;77(20):4049–4067. doi:10.1007/s00018-020-03525-8
   PubMed Web of Science ®Google Scholar
• Szanto A, Bognar Z, Szigeti A, Szabo A, Farkas L, Gallyas F. Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells. Anticancer Res. 2009;29(1):159–164.
   PubMed Web of Science ®Google Scholar
• Dong J, Cheng XD, Zhang WD, Qin JJ. Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation. J Med Chem. 2021;64(13):8884–8915. doi:10.1021/acs.jmedchem.1c00629
   PubMed Web of Science ®Google Scholar
• Chesnokov MS, Khan I, Park Y, et al. The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma. Cancers. 2021;13(6):2.
   Web of Science ®Google Scholar
• Kudaravalli S, den Hollander P, Mani SA. Role of p38 MAP kinase in cancer stem cells and metastasis. Oncogene. 2022;41(23):3177–3185. doi:10.1038/s41388-022-02329-3
   PubMed Web of Science ®Google Scholar
• Li A, Cao W, Liu X, et al. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2020;146(7):1737–1749. doi:10.1007/s00432-020-03228-4
   PubMed Web of Science ®Google Scholar
• Lei ZN, Tian Q, Teng QX, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4(3):e265. doi:10.1002/mco2.265
   PubMedGoogle Scholar